ATE505187T1 - Pharmazeutische zusammensetzung mit verzögerter freisetzung aus tolterodin - Google Patents

Pharmazeutische zusammensetzung mit verzögerter freisetzung aus tolterodin

Info

Publication number
ATE505187T1
ATE505187T1 AT05784596T AT05784596T ATE505187T1 AT E505187 T1 ATE505187 T1 AT E505187T1 AT 05784596 T AT05784596 T AT 05784596T AT 05784596 T AT05784596 T AT 05784596T AT E505187 T1 ATE505187 T1 AT E505187T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
tolterodine
sustained release
release pharmaceutical
composition
Prior art date
Application number
AT05784596T
Other languages
English (en)
Inventor
Andrejka Kramer
Robert Pisek
Tadeja Rajer
Original Assignee
Krka D D Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34926332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE505187(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka D D Novo Mesto filed Critical Krka D D Novo Mesto
Application granted granted Critical
Publication of ATE505187T1 publication Critical patent/ATE505187T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05784596T 2004-08-27 2005-08-23 Pharmazeutische zusammensetzung mit verzögerter freisetzung aus tolterodin ATE505187T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04020431A EP1629834A1 (de) 2004-08-27 2004-08-27 Pharmazeutische Zusammensetzung von Tolterodin mit verzögerter Freisetzung
PCT/EP2005/009102 WO2006021425A1 (en) 2004-08-27 2005-08-23 Sustained release pharmaceutical composition of tolterodine

Publications (1)

Publication Number Publication Date
ATE505187T1 true ATE505187T1 (de) 2011-04-15

Family

ID=34926332

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05784596T ATE505187T1 (de) 2004-08-27 2005-08-23 Pharmazeutische zusammensetzung mit verzögerter freisetzung aus tolterodin

Country Status (7)

Country Link
EP (3) EP1629834A1 (de)
AT (1) ATE505187T1 (de)
DE (1) DE602005027469D1 (de)
EA (1) EA200700484A1 (de)
NO (1) NO20071299L (de)
UA (1) UA87515C2 (de)
WO (1) WO2006021425A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080050449A1 (en) * 2006-03-21 2008-02-28 Dafna Arieli Controlled release formulation of tolterodine
EP1839649A1 (de) * 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Beschichtete Formulierung von Tolterodine
KR100851033B1 (ko) * 2007-02-12 2008-08-12 명문제약주식회사 엘-주석산 톨터로딘 함유 서방성 제제의 제조방법
EP2175843B1 (de) * 2007-08-08 2014-10-08 Inventia Healthcare Private Limited Tolterodinhaltige zusammensetzungen mit verzögerter freisetzung
WO2011061616A2 (en) 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
MX348723B (es) 2011-05-10 2017-06-27 Theravida Inc Combinaciones de solifenacina y estimulantes salivales para el tratamiento de la vejiga hiperactiva.
CN103211784B (zh) * 2012-01-18 2017-07-11 北京天衡药物研究院有限公司 酒石酸托特罗定膜控缓释微丸胶囊
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
RU2718906C2 (ru) 2016-01-20 2020-04-15 Теравида, Инк. Способы и композиции для лечения гипергидроза

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE2061C1 (de) † 1890-01-25
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US6274171B1 (en) † 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
WO1998003067A1 (en) 1996-07-19 1998-01-29 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
SE9803871D0 (sv) † 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
CA2311755C (en) † 1998-08-27 2010-03-23 Pharmacia & Upjohn Ab Therapeutic formulation for administering tolterodine with controlled release
DE19901692C2 (de) † 1999-01-18 2002-06-20 Gruenenthal Gmbh Verfahren zur Herstellung von Pellets mit einem Gehalt von bis zu 90 Gew.% eines pharmazeutischen Wirkstoffes
ES2245320T3 (es) † 1999-11-11 2006-01-01 Pfizer Health Ab Formulacion farmaceutica que contiene tolterodina y su uso.
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
IN191835B (de) 2001-08-03 2004-01-10 Ranbaxy Lab Ltd
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20030152624A1 (en) * 2001-12-20 2003-08-14 Aldrich Dale S. Controlled release dosage form having improved drug release properties
KR100540035B1 (ko) † 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
US7005449B2 (en) 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
CN1150160C (zh) 2002-04-29 2004-05-19 上海医药工业研究院 L－酒石酸托特罗定的合成方法
EP1635795A1 (de) 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Pharmazeutische zusammensetzung mit kontrollierter freigabe von tolterodin sowie deren herstellung

Also Published As

Publication number Publication date
EP1781275B1 (de) 2011-04-13
NO20071299L (no) 2007-05-29
DE602005027469D1 (de) 2011-05-26
WO2006021425A1 (en) 2006-03-02
EP1964553A1 (de) 2008-09-03
UA87515C2 (ru) 2009-07-27
EA200700484A1 (ru) 2007-10-26
EP1629834A1 (de) 2006-03-01
EP1781275A1 (de) 2007-05-09
EP1781275B2 (de) 2014-04-16

Similar Documents

Publication Publication Date Title
ATE505187T1 (de) Pharmazeutische zusammensetzung mit verzögerter freisetzung aus tolterodin
DE502005009109D1 (de) Feste, oral applizierbare pharmazeutische darreichungsformen enthaltend rivaroxaban mit modifizierter freisetzung
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций
CL2007001918A1 (es) Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
UY27720A1 (es) Aroilpiridinonas monocíclicas,
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
ATE415148T1 (de) Feste pharmazeutische zusammensetzung mit donepezilhydrochlorid
ATE400257T1 (de) Stabile pharmazeutische zusammensetzung mit linezolid form iv
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
WO2007098964A3 (en) Pyrrazole derivatives as sigma receptors antagonists
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
DE602006005246D1 (de) Pyridoä2,3-düpyrimidin-derivate sowie deren herstellung und therapeutische anwendung
ATE541573T1 (de) Pharmazeutische zusammensetzung enthaltend lapatinib
CY1108916T1 (el) Υποκαθιστουμενες πυρρολες, οι ενωσεις που τις περιεχουν, διαδικασια παρασκευης και χρηση τους
CR7271A (es) Formulaciones farmaceuticas novedosas a base de melatonina y compuestos similares para su uso en transtornos del sueno
ATE527997T1 (de) Verwendung von aminapthon zur herstellung eines medikaments zur behandlung von arteriopathien
EA200800733A1 (ru) Фармацевтический хитозановый наполнитель для применения в твёрдых лекарственных формах
ATE530172T1 (de) Pharmazeutische formulierungen mit clopidogrel
CY1108865T1 (el) Υποκατεστημενες 2,5-διαμινομευθυλο-1η-πυρρολες

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties